NCT03060720View on ClinicalTrials.gov

Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy

Active, not recruitingOBSERVATIONAL
Enrollment

271

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

April 7, 2019

Study Completion Date

February 28, 2026

Conditions
Pancreatic Cancer
Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT03060720 - Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy | Biotech Hunter | Biotech Hunter